Edwards Lifesciences Corporation $EW Stock Position Boosted by ING Groep NV

Posted by Stanley Muller on Jun 7th, 2026

ING Groep NV boosted its stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 521.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 330,995 shares of the medical research company’s stock after acquiring an additional 277,697 shares during the quarter. ING Groep NV’s holdings in Edwards Lifesciences were worth $28,217,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. Brighton Jones LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at about $266,000. NewEdge Advisors LLC grew its position in Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares in the last quarter. Sei Investments Co. grew its position in Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares in the last quarter. Squarepoint Ops LLC grew its position in Edwards Lifesciences by 277.7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after buying an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina grew its position in Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after buying an additional 1,065 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Barclays reiterated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a report on Wednesday, April 1st. Evercore reaffirmed an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Check Out Our Latest Stock Analysis on EW

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the transaction, the vice president owned 40,411 shares in the company, valued at $3,278,948.54. This represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. This represents a 24.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 95,057 shares of company stock worth $7,874,217 in the last quarter. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW opened at $86.02 on Friday. The firm’s 50 day moving average is $82.22 and its 200-day moving average is $83.07. The stock has a market capitalization of $49.53 billion, a P/E ratio of 45.75, a P/E/G ratio of 2.16 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $89.48.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.